Core Viewpoint - The company, Gilead Sciences (stock code: 1672), announced a financing plan through the placement of existing shares and the issuance of new shares, raising approximately HKD 470 million for clinical trials and operational needs [1] Group 1: Financing Details - The company plans to place 52,400,000 existing shares and issue 28,820,000 new shares at a price of HKD 16.45 per share, representing a discount of about 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [1] - The placement of existing shares accounts for approximately 5.44% of the current issued share capital, while the new shares will represent about 2.99% of the existing share capital [1] - The funds raised will be allocated with approximately HKD 420 million for clinical trials related to subcutaneous and oral peptide candidates for obesity, and about HKD 50 million for working capital and other general corporate purposes [1] Group 2: Regulatory and Completion Aspects - The issuance is conducted under a general mandate granted by the shareholders' meeting, and the subscription will be completed upon meeting relevant conditions, but no later than 14 days after August 19, 2025 [1]

Group 1 - Company Gilead Sciences-B (01672.HK) announced a placement and subscription agreement involving the sale of 52.4 million shares at a price of HKD 16.45 per share, which represents a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18 [1] - The total number of shares being placed represents about 5.44% of the company's issued share capital, while the subscription of 28.82 million shares accounts for approximately 2.90% of the enlarged issued share capital [1] - Following the completion of the placement and subscription, the controlling shareholder's stake will decrease from approximately 62.21% to about 58.03% of the issued share capital [2] Group 2 - The total expected proceeds from the subscription amount to approximately HKD 474 million, with a net amount of about HKD 468 million after deducting commissions and estimated expenses [2] - Approximately 90% of the net proceeds from the subscription are intended for clinical trial development related to subcutaneous and oral peptide candidates for obesity, while about 10% is suggested for working capital and other general corporate purposes [2]

Core Viewpoint - The company, Geely Pharmaceutical, announced a placement and subscription agreement to sell 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18, 2023 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據一九三三年美國證券法（經修訂） 登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將 僅以招股章程的方式進行，該招股章程可向證券發行人或賣方取得，並載有發行人及管理層的 詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 Ascletis Pharma Inc. 歌禮製藥有限公司 （ 於開曼群島註冊成立的有限公司 ） （股份代號：1672） (1)根據一般授權配售現有股份及補足認購新股份 及 (2)補足賣方股份出售 獨家整體協調人及獨家配售代理 由於配售及認購的完 ...

Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and positive developments in its drug pipeline [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Drug Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection, administered once monthly or less frequently, showed a half-life of 36 days in obesity patients during a U.S. Phase Ib study, supporting its potential for less frequent dosing [1]

Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and investor interest [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Product Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expansion indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company has initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection for obesity treatment showed a half-life of 36 days after a single injection in patients, supporting the feasibility of monthly or less frequent dosing [1]

Core Insights - The company announced promising preclinical efficacy results for its obesity treatment candidate ASC47 in combination with the dual-target peptide ASC31 [1][2] - ASC31 is a novel GLP-1R and GIPR dual-target agonist peptide developed by the company, showing favorable pharmacokinetic characteristics and positive in vivo efficacy in DIO mice [1][2] - ASC47 is a selective small molecule agonist of thyroid hormone receptor β (THRβ) designed for monthly subcutaneous injection, targeting fat tissue to achieve high drug concentrations [1] Clinical Study Results - A study comparing low-dose ASC47 (9 mg/kg, subcutaneous) combined with ASC31 (3 nmol/kg, subcutaneous) versus ASC47 combined with terzepatide (3 nmol/kg, subcutaneous) over 14 days showed that the ASC47 and ASC31 combination resulted in an average weight loss of 44.8%, which is 17.6% more than the ASC47 and terzepatide combination (38.1%) [2] - The CEO highlighted the significant differentiation potential of the new therapy compared to existing weight loss drugs and other candidates in development, indicating a robust pipeline for obesity treatments that includes both small molecules and peptides [2]

Core Insights - The company announced promising preclinical efficacy results for its obesity treatment candidates ASC47 and ASC31, which are a combination of a novel GLP-1R/GIPR dual agonist and a selective THRβ agonist [1][2] Group 1: Drug Candidates - ASC31 is a novel GLP-1R and GIPR dual agonist peptide developed by the company, showing good pharmacokinetic characteristics in non-human primates and positive in vivo efficacy in DIO mice [1] - ASC47 is a fat-targeting, once-monthly subcutaneous THRβ selective small molecule agonist, which achieves high drug concentrations in adipose tissue in a dose-dependent manner [1] Group 2: Clinical Study Results - A study comparing low-dose ASC47 (9 mg/kg, subcutaneous) combined with ASC31 (3 nmol/kg, subcutaneous) versus ASC47 combined with teriparatide (3 nmol/kg, subcutaneous) over 14 days showed that the ASC47 and ASC31 combination resulted in an average weight loss of 44.8%, which is 17.6% more than the 38.1% weight loss observed with ASC47 and teriparatide [2] - The CEO highlighted the significant differentiation potential of the new therapy compared to existing weight loss drugs and other candidates in development, indicating a robust pipeline of obesity treatment options that include both small molecules and peptides [2]

Core Insights - The company, Gilead Sciences, has announced promising preclinical efficacy results for its obesity treatment candidates ASC47 and ASC31, which are a combination of a dual receptor agonist and a selective small molecule agonist [1][2] Group 1: Drug Development - ASC31 is a novel GLP-1R and GIPR dual receptor agonist peptide developed by the company, showing favorable pharmacokinetic characteristics in non-human primates and positive in vivo efficacy in DIO mice [1] - ASC47 is a selective small molecule agonist of thyroid hormone receptor β (THRβ) that targets fat and is designed for monthly subcutaneous injection, achieving high drug concentrations in adipose tissue [1] Group 2: Market Potential - The combination of ASC31 and ASC47 demonstrates superior weight loss effects in animal models compared to existing weight loss drugs and other candidates in development, indicating significant differentiation potential in the obesity treatment market [2] - The company is building a robust pipeline of potential obesity therapies that includes both small molecules and peptides, with expectations for future progress updates [2]

Ascletis Pharma Inc. （股份代號：1672） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） － 在飲食誘導肥胖(DIO)小鼠模型中，低劑量ASC47與新型GLP-1R/GIPR雙受 體激動劑多肽ASC31聯用治療14天後，小鼠體重下降44.8%。 － 在DIO小鼠模型中，低劑量ASC47與ASC31聯用的療效（減重44.8%）優於低 劑量ASC47與替爾泊肽聯用（減重38.1%），療效差異具有統計學顯著性。 該DIO小鼠研究旨在對比低劑量ASC47（9 mg/kg，皮下）聯合ASC31（3 nmol/kg， 皮下）與低劑量ASC47（9 mg/kg，皮下）聯合替爾泊肽（3 nmol/kg，皮下）的減 重療效，治療期為14天。結果顯示，ASC47聯合ASC31治療DIO小鼠平均減重 44.8%，比ASC47聯合替爾泊肽(38.1%)多減重17.6%（ p =0.02）。 「我們的 ...